Kyntra Bio Inc (KYNB) – Company Profile and SWOT Analysis

Kyntra Bio Inc (KYNB) – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.

Key Highlights

Kyntra Bio Inc (Kyntra) is a biopharmaceutical company focused on developing novel therapies in the fields of cancer biology and anemia. The company's main activities include the research and development of innovative treatments for life-threatening conditions such as metastatic pancreatic cancer, locally advanced pancreatic cancer, and chemotherapy-induced anemia. Major products under development include Pamrevlumab, a human monoclonal antibody, and Roxadustat, an oral small molecule inhibitor. Kyntra collaborates with partners like AstraZeneca and Astellas Pharma Inc. for the commercialisation of its products in various regions. The company's products are primarily targeted at healthcare providers and patients dealing with cancer and anemia-related conditions. Kyntra operates in multiple geographic locations, with a focus on markets in China, Europe, Japan, and other countries. Kyntra is headquartered in San Francisco, California, the US.

Scope

• Detailed information on Kyntra Bio Inc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Kyntra Bio Inc in the form of a SWOT analysis

• An in-depth view of the business model of Kyntra Bio Inc including a breakdown and examination of key business segments

• News about Kyntra Bio Inc, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Kyntra Bio Inc and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Kyntra Bio Inc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Kyntra Bio Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Kyowa Kirin Co Ltd

Amgen Inc

3SBio Inc

Boehringer Ingelheim International GmbH

Akebia Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Kyntra Bio Inc - Key Facts

Kyntra Bio Inc - Key Employees

Kyntra Bio Inc - Key Employee Biographies

Kyntra Bio Inc - Major Products and Services

Kyntra Bio Inc - History

Kyntra Bio Inc - Company Statement

Kyntra Bio Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Kyntra Bio Inc - Business Description

Geographical Segment: Europe

Performance

Geographical Segment: Japan

Performance

R&D Overview

Kyntra Bio Inc - Corporate Strategy

Kyntra Bio Inc - SWOT Analysis

SWOT Analysis - Overview

Kyntra Bio Inc - Strengths

Kyntra Bio Inc - Weaknesses

Kyntra Bio Inc - Opportunities

Kyntra Bio Inc - Threats

Kyntra Bio Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Kyntra Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026

Kyntra Bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026

Kyntra Bio Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Jun 11, 2026: Kyntra Bio Presents Roxadustat Data Showing Improved Transfusion Independence Regardless of Ring Sideroblast Status in Lower-Risk Myelodysplastic Syndromes

May 11, 2026: Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Mar 17, 2026: Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 09, 2026: Kyntra Bio to Report Fourth Quarter and Full-Year 2025 Financial Results

Feb 17, 2026: Kyntra Bio to Participate in Upcoming Investor Conferences

Nov 10, 2025: FibroGen Reports Third Quarter 2025 Financial Results

Sep 24, 2025: FibroGen Initiates Phase 2 Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer

Aug 18, 2025: FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Aug 11, 2025: FibroGen Reports Second Quarter 2025 Financial Results and Business Update

Jun 09, 2025: FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Kyntra Bio Inc, Key Facts

Kyntra Bio Inc, Key Employees

Kyntra Bio Inc, Key Employee Biographies

Kyntra Bio Inc, Major Products and Services

Kyntra Bio Inc, History

Kyntra Bio Inc, Subsidiaries

Kyntra Bio Inc, Key Competitors

Kyntra Bio Inc, Ratios based on current share price

Kyntra Bio Inc, Annual Ratios

Kyntra Bio Inc, Annual Ratios (Cont…1)

Kyntra Bio Inc, Annual Ratios (Cont…2)

Kyntra Bio Inc, Interim Ratios

Kyntra Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026

Kyntra Bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026

Kyntra Bio Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

FibroGen Inc, Performance Chart (2020 – 2024)

FibroGen Inc, Ratio Charts

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025

FibroGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports